RxDoctor Payments Data

Aaron Marquardt, MD

Hospitalist · West Monroe, LANPI 1538349733

Payments from drug & device makers

$532in general payments, 2019–2025

Across 12 payments — averaging $44.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$153
  • Ceribell, Inc.$105
  • AstraZeneca$104
  • Janssen Products, LP$62
  • Novartis$50
  • Vanda Pharmaceuticals Inc.$22
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$532 in reported general payments places this provider in the 65th percentile of 301 hospitalist providers in Louisiana.

See all hospitalist providers in Louisiana

Medicare billing

Part B allowed, 2024
$113,702
Medicare patients
267
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$20,696
EntrestoSacubitril/Valsartan25$16,348
Albuterol Sulfate HfaAlbuterol Sulfate19$501
CefuroximeCefuroxime Axetil19$262
Amiodarone Hcl17$177
Atorvastatin Calcium23$128
Hydralazine Hcl11$94
Metoprolol Tartrate24$82
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$81
Pantoprazole Sodium18$81
Doxycycline Hyclate12$73
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$70
Carvedilol22$64
Spironolactone13$64
Furosemide19$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$50$16,34825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 301 hospitalist providers in Louisiana.

Other hospitalist in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →